2bal: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="2bal" size="450" color="white" frame="true" align="right" spinBox="true" caption="2bal, resolution 2.10Å" /> '''p38alpha MAP kinase...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:2bal.gif|left|200px]]<br />
[[Image:2bal.gif|left|200px]]<br /><applet load="2bal" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2bal" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2bal, resolution 2.10&Aring;" />
caption="2bal, resolution 2.10&Aring;" />
'''p38alpha MAP kinase bound to pyrazoloamine'''<br />
'''p38alpha MAP kinase bound to pyrazoloamine'''<br />


==Overview==
==Overview==
Inhibition of p38alpha MAP kinase is a potential approach for the, treatment of inflammatory disorders. MKK6-dependent phosphorylation on the, activation loop of p38alpha increases its catalytic activity and affinity, for ATP. An inhibitor, BIRB796, binds at a site used by the purine moiety, of ATP and extends into a "selectivity pocket", which is not used by ATP., It displaces the Asp168-Phe169-Gly170 motif at the start of the activation, loop, promoting a "DFG-out" conformation. Some other inhibitors bind only, in the purine site, with p38alpha remaining in a "DFG-in" conformation. We, now demonstrate that selectivity pocket compounds prevent MKK6-dependent, activation of p38alpha in addition to inhibiting catalysis by activated, p38alpha. Inhibitors using only the purine site do not prevent, MKK6-dependent activation. We present kinetic analyses of seven, inhibitors, whose crystal structures as complexes with p38alpha have been, determined. This work includes four new crystal structures and a novel, assay to measure K(d) for nonactivated p38alpha. Selectivity pocket, compounds associate with p38alpha over 30-fold more slowly than purine, site compounds, apparently due to low abundance of the DFG-out, conformation. At concentrations that inhibit cellular production of an, inflammatory cytokine, TNFalpha, selectivity pocket compounds decrease, levels of phosphorylated p38alpha and beta. Stabilization of a DFG-out, conformation appears to interfere with recognition of p38alpha as a, substrate by MKK6. ATP competes less effectively for prevention of, activation than for inhibition of catalysis. By binding to a different, conformation of the enzyme, compounds that prevent activation offer an, alternative approach to modulation of p38alpha.
Inhibition of p38alpha MAP kinase is a potential approach for the treatment of inflammatory disorders. MKK6-dependent phosphorylation on the activation loop of p38alpha increases its catalytic activity and affinity for ATP. An inhibitor, BIRB796, binds at a site used by the purine moiety of ATP and extends into a "selectivity pocket", which is not used by ATP. It displaces the Asp168-Phe169-Gly170 motif at the start of the activation loop, promoting a "DFG-out" conformation. Some other inhibitors bind only in the purine site, with p38alpha remaining in a "DFG-in" conformation. We now demonstrate that selectivity pocket compounds prevent MKK6-dependent activation of p38alpha in addition to inhibiting catalysis by activated p38alpha. Inhibitors using only the purine site do not prevent MKK6-dependent activation. We present kinetic analyses of seven inhibitors, whose crystal structures as complexes with p38alpha have been determined. This work includes four new crystal structures and a novel assay to measure K(d) for nonactivated p38alpha. Selectivity pocket compounds associate with p38alpha over 30-fold more slowly than purine site compounds, apparently due to low abundance of the DFG-out conformation. At concentrations that inhibit cellular production of an inflammatory cytokine, TNFalpha, selectivity pocket compounds decrease levels of phosphorylated p38alpha and beta. Stabilization of a DFG-out conformation appears to interfere with recognition of p38alpha as a substrate by MKK6. ATP competes less effectively for prevention of activation than for inhibition of catalysis. By binding to a different conformation of the enzyme, compounds that prevent activation offer an alternative approach to modulation of p38alpha.


==About this Structure==
==About this Structure==
2BAL is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with PQA as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2BAL OCA].  
2BAL is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=PQA:'>PQA</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2BAL OCA].  


==Reference==
==Reference==
Line 17: Line 16:
[[Category: Breed, J.]]
[[Category: Breed, J.]]
[[Category: Gerhardt, S.]]
[[Category: Gerhardt, S.]]
[[Category: Norman, R.A.]]
[[Category: Norman, R A.]]
[[Category: Pauptit, R.A.]]
[[Category: Pauptit, R A.]]
[[Category: Read, J.]]
[[Category: Read, J.]]
[[Category: Tucker, J.]]
[[Category: Tucker, J.]]
Line 26: Line 25:
[[Category: serine/threonine kinase]]
[[Category: serine/threonine kinase]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 21:00:19 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:35:44 2008''